A human ICAM-1 antibody isolated by a function-first approach has potent macrophage-dependent antimyeloma activity in vivo

Cancer Cell

Volumn 23, Issue 4, 2013, Pages 502-515

  Veitonmäki, Niina ^a,e   Hansson, Markus ^b   Zhan, Fenghuang ^c   Sundberg, Annika ^a   Löfstedt, Tobias ^a   Ljungars, Anne ^a   Li, Zhan Chun ^a   Martinsson Niskanen, Titti ^a   Zeng, Ming ^d   Yang, Ye ^c   Danielsson, Lena ^a   Kovacek, Mathilda ^a   Lundqvist, Andrea ^a   Mårtensson, Linda ^a   Teige, Ingrid ^a   Tricot, Guido ^c   Frendéus, Björn ^a  

^a BioInvent International AB   (Sweden)

^b LUND UNIVERSITY HOSPITAL   (Sweden)

^c UNIVERSITY OF IOWA   (United States)

^d CENTRAL SOUTH UNIVERSITY   (China)

^e Alligator Bioscience   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

B LYMPHOCYTE ANTIBODY; BI 505 ANTIBODY; BORTEZOMIB; DEXAMETHASONE; IMMUNOGLOBULIN G; INTERCELLULAR ADHESION MOLECULE 1; LENALIDOMIDE; MELPHALAN; RITUXIMAB; UNCLASSIFIED DRUG;

ADULT; AGED; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY ISOLATION; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER RECURRENCE; CANCER SURVIVAL; CLINICAL ARTICLE; FEMALE; HUMAN; HUMAN CELL; IN VIVO STUDY; MACROPHAGE; MALE; MOUSE; MULTIPLE CYCLE TREATMENT; MULTIPLE MYELOMA; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION;

EID: 84876385896     PISSN: 15356108     EISSN: 18783686     Source Type: Journal    
DOI: 10.1016/j.ccr.2013.02.026     Document Type: Article

References (43)

1. Aalinkeel R., Nair M.P.N., Sufrin G., Mahajan S.D., Chadha K.C., Chawda R.P., Schwartz S.A. Gene expression of angiogenic factors correlates with metastatic potential of prostate cancer cells. Cancer Res. 2004, 64:5311-5321.
2. Alduaij W., Illidge T.M. The future of anti-CD20 monoclonal antibodies: are we making progress?. Blood 2011, 117:2993-3001.
3. Beck A., Wurch T., Bailly C., Corvaia N. Strategies and challenges for the next generation of therapeutic antibodies. Nat. Rev. Immunol. 2010, 10:345-352.
4. Beers S.A., Chan C.H., James S., French R.R., Attfield K.E., Brennan C.M., Ahuja A., Shlomchik M.J., Cragg M.S., Glennie M.J. Type II (tositumomab) anti-CD20 monoclonal antibody out performs type I (rituximab-like) reagents in B-cell depletion regardless of complement activation. Blood 2008, 112:4170-4177.
5. Bibeau F., Lopez-Crapez E., Di Fiore F., Thezenas S., Ychou M., Blanchard F., Lamy A., Penault-Llorca F., Frébourg T., Michel P., et al. Impact of FcgammaRIIa-FcgammaRIIIa polymorphisms and KRAS mutations on the clinical outcome of patients with metastatic colorectal cancer treated with cetuximab plus irinotecan. J. Clin. Oncol. 2009, 27:1122-1129.
6. Cheson B.D., Leonard J.P. Monoclonal antibody therapy for B-cell non-Hodgkin's lymphoma. N. Engl. J. Med. 2008, 359:613-626.
7. Clynes R.A., Towers T.L., Presta L.G., Ravetch J.V. Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets. Nat. Med. 2000, 6:443-446.
8. Cragg M.S., Glennie M.J. Antibody specificity controls in vivo effector mechanisms of anti-CD20 reagents. Blood 2004, 103:2738-2743.
9. Cragg M.S., Morgan S.M., Chan H.T., Morgan B.P., Filatov A.V., Johnson P.W., French R.R., Glennie M.J. Complement-mediated lysis by anti-CD20 mAb correlates with segregation into lipid rafts. Blood 2003, 101:1045-1052.
10. Fransson J., Tornberg U.C., Borrebaeck C.A., Carlsson R., Frendéus B. Rapid induction of apoptosis in B-cell lymphoma by functionally isolated human antibodies. Int. J. Cancer 2006, 119:349-358.
11. Gan H.K., Lappas M., Cao D.X., Cvrljevdic A., Scott A.M., Johns T.G. Targeting a unique EGFR epitope with monoclonal antibody 806 activates NF-kappaB and initiates tumour vascular normalization. J. Cell. Mol. Med. 2009, 13(9B):3993-4001.
12. Hideshima T., Mitsiades C., Tonon G., Richardson P.G., Anderson K.C. Understanding multiple myeloma pathogenesis in the bone marrow to identify new therapeutic targets. Nat. Rev. Cancer 2007, 7:585-598.
13. Huang Y.W., Richardson J.A., Vitetta E.S. Anti-CD54 (ICAM-1) has antitumor activity in SCID mice with human myeloma cells. Cancer Res. 1995, 55:610-616.
14. Ivanov A., Beers S.A., Walshe C.A., Honeychurch J., Alduaij W., Cox K.L., Potter K.N., Murray S., Chan C.H., Klymenko T., et al. Monoclonal antibodies directed to CD20 and HLA-DR can elicit homotypic adhesion followed by lysosome-mediated cell death in human lymphoma and leukemia cells. J. Clin. Invest. 2009, 119:2143-2159.
15. Johnson J.P., Stade B.G., Hupke U., Holzmann B., Riethmüller G. The melanoma progression-associated antigen P3.58 is identical to the intercellular adhesion molecule, ICAM-1. Immunobiology 1988, 178:275-284.
16. Kapoor P., Greipp P.T., Morice W.G., Rajkumar S.V., Witzig T.E., Greipp P.R. Anti-CD20 monoclonal antibody therapy in multiple myeloma. Br. J. Haematol. 2008, 141:135-148.
17. Kavanaugh A.F., Schulze-Koops H., Davis L.S., Lipsky P.E. Repeat treatment of rheumatoid arthritis patients with a murine anti-intercellular adhesion molecule 1 monoclonal antibody. Arthritis Rheum. 1997, 40:849-853.
18. Kyle R.A., Rajkumar S.V. Multiple myeloma. N. Engl. J. Med. 2004, 351:1860-1873.
19. Lejeune J., Thibault G., Ternant D., Cartron G., Watier H., Ohresser M. Evidence for linkage disequilibrium between Fcgamma RIIIa-V158F and Fcgamma RIIa-H131R polymorphisms in white patients, and for an Fcgamma RIIIa-restricted influence on the response to therapeutic antibodies. J. Clin. Oncol. 2008, 26:5489-5491. author reply 5491-5492.
20. Lim S.H., Beers S.A., French R.R., Johnson P.W., Glennie M.J., Cragg M.S. Anti-CD20 monoclonal antibodies: historical and future perspectives. Haematologica 2010, 95:135-143.
21. Manches O., Lui G., Chaperot L., Gressin R., Molens J.P., Jacob M.C., Sotto J.J., Leroux D., Bensa J.C., Plumas J. In vitro mechanisms of action of rituximab on primary non-Hodgkin lymphomas. Blood 2003, 101:949-954.
22. Mileski W.J., Burkhart D., Hunt J.L., Kagan R.J., Saffle J.R., Herndon D.N., Heimbach D.M., Luterman A., Yurt R.W., Goodwin C.W., Hansborough J. Clinical effects of inhibiting leukocyte adhesion with monoclonal antibody to intercellular adhesion molecule-1 (enlimomab) in the treatment of partial-thickness burn injury. J. Trauma 2003, 54:950-958.
23. Mitsiades C.S., Mitsiades N.S., Bronson R.T., Chauhan D., Munshi N., Treon S.P., Maxwell C.A., Pilarski L., Hideshima T., Hoffman R.M., Anderson K.C. Fluorescence imaging of multiple myeloma cells in a clinically relevant SCID/NOD in vivo model: biologic and clinical implications. Cancer Res. 2003, 63:6689-6696.
24. Musolino A., Naldi N., Bortesi B., Pezzuolo D., Capelletti M., Missale G., Laccabue D., Zerbini A., Camisa R., Bisagni G., et al. Immunoglobulin G fragment C receptor polymorphisms and clinical efficacy of trastuzumab-based therapy in patients with HER-2/neu-positive metastatic breast cancer. J. Clin. Oncol. 2008, 26:1789-1796.
25. Nimmerjahn F., Bruhns P., Horiuchi K., Ravetch J.V. FcgammaRIV: a novel FcR with distinct IgG subclass specificity. Immunity 2005, 23:41-51.
26. Park S., Jiang Z., Mortenson E.D., Deng L., Radkevich-Brown O., Yang X., Sattar H., Wang Y., Brown N.K., Greene M., et al. The therapeutic effect of anti-HER2/neu antibody depends on both innate and adaptive immunity. Cancer Cell 2010, 18:160-170.
27. Rawstron A.C., Orfao A., Beksac M., Bezdickova L., Brooimans R.A., Bumbea H., Dalva K., Fuhler G., Gratama J., Hose D., et al. Report of the European Myeloma Network on multiparametric flow cytometry in multiple myeloma and related disorders. Haematologica 2008, 93:431-438. European Myeloma Network.
28. Richardson P.G., Lonial S., Jakubowiak A.J., Harousseau J.L., Anderson K.C. Monoclonal antibodies in the treatment of multiple myeloma. Br. J. Haematol. 2011, Published online July 21, 2011. 10.1111/j.1365-2141.2011.08790.
29. Sampaio M.S., Vettore A.L., Yamamoto M., Chauffaille Mde.L., Zago M.A., Colleoni G.W. Expression of eight genes of nuclear factor-kappa B pathway in multiple myeloma using bone marrow aspirates obtained at diagnosis. Histol. Histopathol. 2009, 24:991-997.
30. Schmidmaier R., Baumann P., Simsek M., Dayyani F., Emmerich B., Meinhardt G. The HMG-CoA reductase inhibitor simvastatin overcomes cell adhesion-mediated drug resistance in multiple myeloma by geranylgeranylation of Rho protein and activation of Rho kinase. Blood 2004, 104:1825-1832.
31. Schmidmaier R., Mörsdorf K., Baumann P., Emmerich B., Meinhardt G. Evidence for cell adhesion-mediated drug resistance of multiple myeloma cells in vivo. Int. J. Biol. Markers 2006, 21:218-222.
32. Schneider D., Berrouschot J., Brandt T., Hacke W., Ferbert A., Norris S.H., Polmar S.H., Schäfer E. Safety, pharmacokinetics and biological activity of enlimomab (anti-ICAM-1 antibody): an open-label, dose escalation study in patients hospitalized for acute stroke. Eur. Neurol. 1998, 40:78-83.
33. Smith M.R. Rituximab (monoclonal anti-CD20 antibody): mechanisms of action and resistance. Oncogene 2003, 22:7359-7368.
34. Söderlind E., Strandberg L., Jirholt P., Kobayashi N., Alexeiva V., Aberg A.M., Nilsson A., Jansson B., Ohlin M., Wingren C., et al. Recombining germline-derived CDR sequences for creating diverse single-framework antibody libraries. Nat. Biotechnol. 2000, 18:852-856.
35. Stebbings R., Findlay L., Edwards C., Eastwood D., Bird C., North D., Mistry Y., Dilger P., Liefooghe E., Cludts I., et al. "Cytokine storm" in the phase I trial of monoclonal antibody TGN1412: better understanding the causes to improve preclinical testing of immunotherapeutics. J. Immunol. 2007, 179:3325-3331.
36. van der Kolk L.E., Grillo-López A.J., Baars J.W., Hack C.E., van Oers M.H. Complement activation plays a key role in the side-effects of rituximab treatment. Br. J. Haematol. 2001, 115:807-811.
37. Weiner L.M., Surana R., Wang S. Monoclonal antibodies: versatile platforms for cancer immunotherapy. Nat. Rev. Immunol. 2010, 10:317-327.
38. Weng W.K., Levy R. Two immunoglobulin G fragment C receptor polymorphisms independently predict response to rituximab in patients with follicular lymphoma. J. Clin. Oncol. 2003, 21:3940-3947.
39. Wilson N.S., Yang B., Yang A., Loeser S., Marsters S., Lawrence D., Li Y., Pitti R., Totpal K., Yee S., et al. An Fcγ receptor-dependent mechanism drives antibody-mediated target-receptor signaling in cancer cells. Cancer Cell 2011, 19:101-113.
40. Yaccoby S., Barlogie B., Epstein J. Primary myeloma cells growing in SCID-hu mice: a model for studying the biology and treatment of myeloma and its manifestations. Blood 1998, 92:2908-2913.
41. Zhang W., Gordon M., Schultheis A.M., Yang D.Y., Nagashima F., Azuma M., Chang H.M., Borucka E., Lurje G., Sherrod A.E., et al. FCGR2A and FCGR3A polymorphisms associated with clinical outcome of epidermal growth factor receptor expressing metastatic colorectal cancer patients treated with single-agent cetuximab. J. Clin. Oncol. 2007, 25:3712-3718.
42. Zheng Y., Cai Z., Wang S., Zhang X., Qian J., Hong S., Li H., Wang M., Yang J., Yi Q. Macrophages are an abundant component of myeloma microenvironment and protect myeloma cells from chemotherapy drug-induced apoptosis. Blood 2009, 114:3625-3628.
43. Zheng Y., Yang J., Qian J., Qiu P., Hanabuchi S., Lu Y., Wang Z., Liu Z., Li H., He J., et al. PSGL-1/selectin and ICAM-1/CD18 interactions are involved in macrophage-induced drug resistance in myeloma. Leukemia 2012, Published online September 21, 2012. 10.1038/leu.2012.272.